AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Esperion TherapeuticsRevance TherapeuticsMyovant SciencesPhathom PharmaceuticalsOdonate Therapeutics
SymbolNASDAQ:ESPRNASDAQ:RVNCNYSE:MYOVNASDAQ:PHATNASDAQ:ODT
Price Information
Current Price$52.71$26.08$19.34$31.55$38.88
52 Week RangeBuyBuyBuyBuySell
Beat the Market™ Rank
Overall Score1.41.31.91.51.0
Analysis Score4.32.43.42.30.5
Community Score2.82.62.62.52.1
Dividend Score0.00.00.00.00.0
Ownership Score0.01.03.02.02.0
Earnings & Valuation Score0.00.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuySell
Consensus Price Target$81.46$28.71$30.67$37.00$26.00
% Upside from Price Target54.55% upside10.10% upside58.57% upside17.27% upside-33.13% downside
Trade Information
Market Cap$1.40 billion$1.47 billion$1.74 billion$936.71 million$1.27 billion
Beta2.131.652.61N/A1.15
Average Volume775,592781,4521,077,76682,93081,424
Sales & Book Value
Annual Revenue$148.36 million$410,000.00N/AN/AN/A
Price / Sales9.813,629.06N/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.73 per share$5.00 per share($1.21) per share$9.29 per share$5.06 per share
Price / Book72.215.22N/AN/AN/A
Profitability
Net Income$-97,170,000.00$-159,430,000.00$-288,990,000.00$-255,130,000.00$-111,820,000.00
EPS($3.59)($3.67)($3.37)($13.98)($4.05)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-5,492.02%N/AN/AN/AN/A
Return on Equity (ROE)-627.38%-85.18%-2,288.94%N/A-67.21%
Return on Assets (ROA)-109.71%-49.78%-172.45%N/A-58.26%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.06%0.64%N/A0.22%N/A
Current Ratio2.35%12.45%1.02%57.22%6.28%
Quick Ratio2.33%12.45%1.02%57.22%6.28%
Ownership Information
Institutional Ownership PercentageN/A86.63%34.22%74.90%95.78%
Insider Ownership Percentage7.70%4.80%3.68%39.80%48.90%
Miscellaneous
Employees761708612117
Shares Outstanding27.62 million57.05 million89.87 million28.97 million32.11 million
Next Earnings Date8/13/2020 (Estimated)8/3/2020 (Estimated)8/4/2020 (Estimated)8/11/2020 (Estimated)7/22/2020 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.